A recently posted preprint systematic review in medRxiv has assessed the economic impact of the COVID-19 pandemic on healthcare systems and society worldwide. The researchers filtered over 10,000 papers, selecting 41 of them for economic analysis. Data from several countries and provinces showed […]
Value in Health Regional Issues: Cost-Effectiveness of Novel Kidney Disease Biomarker Screening
IgA nephropathy (IgAN) is a leading cause of end-stage kidney disease across the world. A new paper in Value in Health Regional explores the cost-effectiveness of screening for IgAN in Japan using novel biomarkers. Using an analytical decision model, researchers found that screening could […]
New Value in Health Article: Limitations of Conventional Cost-Effectiveness Analysis and the ISPOR Value Flower
Conventional methods of cost-effectiveness often overlook key value elements for patients. The “ISPOR Value Flower,” introduced in the 2018 ISPOR Special Task Force (STF) on US Value Assessments, is a model for augmented value-assessment that accounts for several of these novel, underappreciated […]
Course Available: Introduction to Health Economics and Outcomes Research
A new course is being offered by ISPOR to teach clinicians the basics of health economics and outcomes research. Participants will learn to incorporate concepts from health economics into their data analysis and study design. In addition, the course will cover budget impact analysis models and was […]
Interview: David Kim Talks about the Tufts Cost-Effectiveness Analyzer (CEA) Registry
Assistant professor David Kim speaks with Rachel Breslau about his role as program director of the Tufts cost-effectiveness analyzer (CEA) registry in a new Center for the Evaluation of Value and Risk in Health (CEVR) interview. In the interview, Kim speaks about his path into the health economic […]
JAMA Report Investigates Cost-effectiveness Studies for Cancer Drugs
In a new article in the Journal of the American Medical Association, researchers Alyson Haslam, PhD, Mark P. Lythgoe, MD, and Emma Greenstreet Akman, et al. probe 228 cost-effectiveness studies, 116 drug approvals, and 254 analyses. Upon investigation, studies funded by pharmaceutical companies were […]
Gene Therapy for Beta Thalassemia Gene Under ICER Assessment
A gene therapy for beta thalassemia will undergo ICER assessment for comparative clinical effectiveness and value. Betibeglogene autotemcel (Zynteglo/LentiGlobin) from Bluebird Bio will likely receive an FDA decision by mid-2022. ICER has released an outline of its strategy for the assessment. It […]
Are Mammograms After 75 Worth It?
Uncertainty is building regarding the value of mammograms for breast cancer screening after 75 years of age according to a study published in the journal Annals of Internal Medicine. The harms of overdiagnosis may outweigh the human and economic benefits of the relatively small number of breast […]
Establishing the Value of Next-Gen Sequencing
Next-generation sequencing (NGS) has been touted by some as the backbone of future precision medicine approaches. This technology could help target treatment to the right patient population, preserving medical resources, reducing hospitalization, and improving patient outcomes. However, there is no […]
ISPOR Boosts HEOR in Low & Middle-Income Countries
ISPOR pledged to promote HEOR efforts in low- to middle-income countries (LMICs) in its Strategic Plan 2024. LMICs often face difficulties attaining the financial resources for healthcare spending and are disproportionately impacted by events like the global pandemic. ISPOR has long supported HEOR […]
